Published in Cancer Cell on October 01, 2005
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 8.82
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab (2008) 6.60
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 6.30
Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A (2011) 5.24
The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev (2007) 4.13
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature (2012) 3.85
Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 3.62
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation. Nat Immunol (2014) 3.31
Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res (2009) 3.15
Cellular fatty acid metabolism and cancer. Cell Metab (2013) 2.82
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer (2006) 2.70
Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity (2014) 2.63
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev (2009) 2.54
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell (2010) 2.50
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol (2012) 2.35
Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A (2007) 2.34
Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol (2008) 2.34
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev (2011) 2.20
Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells. J Biotechnol (2009) 2.08
Cancer metabolism: current perspectives and future directions. Cell Death Dis (2012) 2.07
T cell metabolism drives immunity. J Exp Med (2015) 2.06
De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer (2009) 2.05
A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res (Phila) (2009) 1.95
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab (2013) 1.93
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab (2014) 1.92
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta (2010) 1.88
Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol (2016) 1.83
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab (2014) 1.74
Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol (2015) 1.68
Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol (2006) 1.65
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene (2010) 1.63
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech (2013) 1.55
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell (2015) 1.52
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol (2016) 1.51
Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med (2008) 1.50
MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol (2006) 1.48
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Targeting glycogen metabolism in bladder cancer. Nat Rev Urol (2015) 1.46
Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell (2010) 1.42
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS One (2009) 1.42
The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci U S A (2009) 1.42
Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. Oncogene (2010) 1.41
Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev (2013) 1.40
Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med (2013) 1.39
The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell (2011) 1.37
The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget (2012) 1.33
Metabolism strikes back: metabolic flux regulates cell signaling. Genes Dev (2010) 1.33
Dysregulated lipid metabolism in cancer. World J Biol Chem (2012) 1.27
Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 1.27
Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell (2013) 1.25
Carbon metabolism-mediated myogenic differentiation. Nat Chem Biol (2010) 1.25
Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J (2010) 1.23
Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell (2009) 1.23
Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem (2008) 1.23
Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med (2015) 1.19
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ (2012) 1.19
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res (2014) 1.19
Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab (2015) 1.17
Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 1.16
Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A (2014) 1.14
PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Mol Cell (2015) 1.14
Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des (2014) 1.11
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer (2010) 1.11
Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res (2008) 1.10
Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10
Targeting glucose metabolism in patients with cancer. Cancer (2013) 1.10
Cancer's craving for sugar: an opportunity for clinical exploitation. J Cancer Res Clin Oncol (2009) 1.09
UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. J Clin Invest (2015) 1.09
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol (2012) 1.08
Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab Eng (2012) 1.08
Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther (2008) 1.08
Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics (2007) 1.05
FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res (2014) 1.05
Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev (2011) 1.04
Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett (2013) 1.04
Acetate produced in the mitochondrion is the essential precursor for lipid biosynthesis in procyclic trypanosomes. Proc Natl Acad Sci U S A (2009) 1.04
Autophagy: a targetable linchpin of cancer cell metabolism. Trends Endocrinol Metab (2013) 1.04
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell (2005) 17.81
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 11.71
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell (2005) 11.19
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol (2004) 8.85
ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 8.82
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol (2005) 7.11
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 6.30
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev (2004) 6.08
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood (2008) 5.43
Maximizing mouse cancer models. Nat Rev Cancer (2007) 5.38
Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol (2004) 5.31
Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5.29
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A (2011) 5.24
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell (2002) 5.06
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Necrotic death as a cell fate. Genes Dev (2006) 4.93
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity (2007) 4.74
AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science (2009) 4.72
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 4.71
Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell (2010) 4.62
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene (2005) 4.28
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell (2006) 4.20
The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev (2007) 4.13
HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell (2007) 4.10
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 3.98
Akt-dependent transformation: there is more to growth than just surviving. Oncogene (2005) 3.91
Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol (2003) 3.84
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell (2006) 3.66
Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell (2004) 3.62
Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol (2002) 3.58
Revving the engine: signal transduction fuels T cell activation. Immunity (2007) 3.57
Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol (2003) 3.52
Autophagy: basic principles and relevance to disease. Annu Rev Pathol (2008) 3.52
ATP citrate lyase is an important component of cell growth and transformation. Oncogene (2005) 3.48
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J Biol Chem (2006) 3.45
The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev (2010) 3.40
The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res (2007) 3.35
Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med (2009) 3.24
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13
The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol (2002) 3.08
Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science (2010) 3.05
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev (2011) 2.97
The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat Cell Biol (2005) 2.94
Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. Proc Natl Acad Sci U S A (2011) 2.91